异动解读｜科伦博泰生物盘中上涨10.8%，核心产品联治PD-L1阴性NSCLC三期研究达主要终点

行情直击07-15

7月15日，科伦博泰生物盘中上涨10.8%，报552.0港元，成交额4.64亿港元。

消息面上，公司宣布核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的三期临床研究已达到主要终点，安全性与既往研究一致，未观察到新的安全性信号。此前公司已在ASCO大会披露sac-TMT联合K药一线治疗PD-L1阳性NSCLC的三期阳性结果，本次PD-L1阴性适应症的突破进一步扩大其覆盖人群范围。国联民生证券此前研报指出，科伦博泰及合作方默沙东在PD-1单抗+ADC路线中兼具适应症覆盖范围与较高成功概率，有望在该路线中胜出。目前公司已在中国开展9项注册性临床研究。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1132262891?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132262891","market":"us","top_or_hot":-1,"title":"异动解读｜科伦博泰生物盘中上涨10.8%，核心产品联治PD-L1阴性NSCLC三期研究达主要终点","media":"行情直击","content":"<p><p>7月15日，科伦博泰生物盘中上涨10.8%，报552.0港元，成交额4.64亿港元。</p><p>消息面上，公司宣布核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的三期临床研究已达到主要终点，安全性与既往研究一致，未观察到新的安全性信号。此前公司已在ASCO大会披露sac-TMT联合K药一线治疗PD-L1阳性NSCLC的三期阳性结果，本次PD-L1阴性适应症的突破进一步扩大其覆盖人群范围。国联民生证券此前研报指出，科伦博泰及合作方默沙东在PD-1单抗+ADC路线中兼具适应症覆盖范围与较高成功概率，有望在该路线中胜出。目前公司已在中国开展9项注册性临床研究。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜科伦博泰生物盘中上涨10.8%，核心产品联治PD-L1阴性NSCLC三期研究达主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜科伦博泰生物盘中上涨10.8%，核心产品联治PD-L1阴性NSCLC三期研究达主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n2026-07-15 10:38 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月15日，科伦博泰生物盘中上涨10.8%，报552.0港元，成交额4.64亿港元。消息面上，公司宣布核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的三期临床研究已达到主要终点，安全性与既往研究一致，未观察到新的安全性信号。此前公司已在ASCO大会披露sac-TMT联合K药一线治疗PD-L1阳性NSCLC的三期阳性...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1132262891","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132262891","pubTimestamp":1784083130,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"7月15日，科伦博泰生物盘中上涨10.8%，报552.0港元，成交额4.64亿港元。消息面上，公司宣布核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的三期临床研究已达到主要终点，安全性与既往研究一致，未观察到新的安全性信号。此前公司已在ASCO大会披露sac-TMT联合K药一线治疗PD-L1阳性NSCLC的三期阳性结果，本次PD-L1阴性适应症的突破进一步扩大其覆盖人群范围。目前公司已在中国开展9项注册性临床研究。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"Interpretation of the change | Kelunbotai Biotech rose by 10.8% in the intraday session, and the phase III study of the core product combined treatment of PD-L1-negative NSCLC reached the primary endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"7月15日，科伦博泰生物盘中上涨10.8%，报552.0港元，成交额4.64亿港元。消息面上，公司宣布核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的三期临床研究已达到主要终点，安全性与既往研究一致，未观察到新的安全性信号。此前公司已在ASCO大会披露sac-TMT联合K药一线治疗PD-L1阳性NSCLC的三期阳性结果，本次PD-L1阴性适应症的突破进一步扩大其覆盖人群范围。国联民生证券此前研报指出，科伦博泰及合作方默沙东在PD-1单抗+ADC路线中兼具适应症覆盖范围与较高成功概率，有望在该路线中胜出。目前公司已在中国开展9项注册性临床研究。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132262891","isCrawlerRequest":true}